LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 200

Search options

  1. Article ; Online: "Japan Diet" and Health-The Present and Future.

    Teramoto, Tamio

    Journal of nutritional science and vitaminology

    2019  Volume 65, Issue Supplement, Page(s) S29–S33

    Abstract: Japan achieved remarkable economic development after World War II, which has led remarkable changes in risk factors of atherosclerotic diseases and led to epidemiological transition in Japan. Nowadays, obesity is pandemic around world, which is same case ...

    Abstract Japan achieved remarkable economic development after World War II, which has led remarkable changes in risk factors of atherosclerotic diseases and led to epidemiological transition in Japan. Nowadays, obesity is pandemic around world, which is same case in Japan. BMI of Japanese population, especially young adult men increased gradually since the 1960s associated with increase in intake of fat as well as decrease in intake of rice, which has been revealed by the annual report of the Ministry of Health, Labour and Welfare. Such changes suggest the change of dietary habit from Japanese style to westernized style. In recent years such changes in lifestyle has been accompanied by a gradual increase in serum cholesterol in the Japanese population, which is associated with increase in the incidence of cardiovascular diseases (CVD). Japanese guidelines recommend "The Japan diet" to prevent CVD, because there are several epidemiological data to show the cardio-preventive effect of fish, soy bean, and vegetables, which are the major component of "The Japan Diet". It is very important to recognize the diet habit is one of culture and that rice plays a pivotal role in "The Japan Diet".
    MeSH term(s) Adult ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Diet/adverse effects ; Diet, Healthy/methods ; Feeding Behavior ; Female ; Humans ; Incidence ; Japan/epidemiology ; Male ; Middle Aged ; Nutrition Policy/trends ; Obesity/epidemiology ; Obesity/etiology ; Obesity/prevention & control ; Risk Factors ; Young Adult
    Language English
    Publishing date 2019-10-16
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 191366-9
    ISSN 1881-7742 ; 0301-4800
    ISSN (online) 1881-7742
    ISSN 0301-4800
    DOI 10.3177/jnsv.65.S29
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 596: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Extending the "Lower is Better" Principle to Japanese and Possibly Other Asian Populations.

    Teramoto, Tamio

    Circulation

    2018  Volume 137, Issue 19, Page(s) 2010–2012

    MeSH term(s) Cholesterol, LDL ; Coronary Artery Disease ; Humans ; Quinolines
    Chemical Substances Cholesterol, LDL ; Quinolines ; pitavastatin (M5681Q5F9P)
    Language English
    Publishing date 2018-04-18
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 80099-5
    ISSN 1524-4539 ; 0009-7322 ; 0069-4193 ; 0065-8499
    ISSN (online) 1524-4539
    ISSN 0009-7322 ; 0069-4193 ; 0065-8499
    DOI 10.1161/CIRCULATIONAHA.117.033001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui IV Zs.60: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Is "The Japan Diet" Cardioprotective?

    Teramoto, Tamio

    Journal of atherosclerosis and thrombosis

    2016  Volume 24, Issue 4, Page(s) 388–389

    MeSH term(s) Cardiovascular Diseases/prevention & control ; Healthy Diet ; Humans
    Language English
    Publishing date 2016-10-12
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 2011474-6
    ISSN 1880-3873 ; 1340-3478
    ISSN (online) 1880-3873
    ISSN 1340-3478
    DOI 10.5551/jat.ED061
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5192: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: [Atherosclerosis: progress in diagnosis and treatments. Editorial: prevention of atherosclerotic diseases through diagnosis and management of the risk factors].

    Teramoto, Tamio

    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine

    2013  Volume 102, Issue 2, Page(s) 271–273

    MeSH term(s) Atherosclerosis/diagnosis ; Atherosclerosis/epidemiology ; Atherosclerosis/prevention & control ; Atherosclerosis/therapy ; Humans ; Japan ; Practice Guidelines as Topic/standards ; Risk Factors
    Language Japanese
    Publishing date 2013-05-12
    Publishing country Japan
    Document type Editorial
    ZDB-ID 952816-7
    ISSN 1883-2083 ; 0021-5384
    ISSN (online) 1883-2083
    ISSN 0021-5384
    DOI 10.2169/naika.102.271
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 594: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C.

    Teramoto, Tamio

    Expert opinion on pharmacotherapy

    2012  Volume 13, Issue 6, Page(s) 859–865

    Abstract: Introduction: Statins are currently the most effective drugs for lowering low-density lipoprotein cholesterol (LDL-C) and represent the first choice for treating hypercholesterolemia. Pitavastatin was launched as a new statin on the Japanese market in ... ...

    Abstract Introduction: Statins are currently the most effective drugs for lowering low-density lipoprotein cholesterol (LDL-C) and represent the first choice for treating hypercholesterolemia. Pitavastatin was launched as a new statin on the Japanese market in 2003, followed by Korea, Thailand, China, the United States and Europe. This review summarizes and evaluates new insights into pitavastatin, from clinical trials since 2010.
    Areas covered: This article reviews studies that compare pitavastatin with various other statins: i) Randomized Head-to-Head Comparison of Pitavastatin, Atorvastatin, and Rosuvastatin for Safety and Efficacy (Quantity and Quality of LDL): the PATROL Trial; ii) various Phase III clinical trials in Western countries; iii) The Comparison of Preventive Effect on Cardiovascular Events With Different Statins (CIRCLE) study; and iv) The Livalo Effectiveness and Safety (LIVES) Study Extension. Pitavastatin was found to have a similar LDL-C-lowering effect to other strong statins but also had a strong HDL-C-elevating effect and did not worsen glucose metabolism.
    Expert opinion: Pitavastatin has been launched in various countries around the world as a statin with potent LDL-C-lowering activity that is virtually unmetabolized by the cytochrome P450 family, with relatively few drug-drug interactions and no adverse effects on blood glucose. Pitavastatin thus appears well suited to long-term use.
    MeSH term(s) Cholesterol, HDL/blood ; Cholesterol, LDL/blood ; Clinical Trials, Phase III as Topic ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypercholesterolemia/blood ; Hypercholesterolemia/drug therapy ; Quinolines/therapeutic use ; Randomized Controlled Trials as Topic
    Chemical Substances Cholesterol, HDL ; Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Quinolines ; pitavastatin (M5681Q5F9P)
    Language English
    Publishing date 2012-04
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1517/14656566.2012.660525
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5130: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: [Significance of clinical pathology in the field of internal medicine].

    Teramoto, Tamio

    Rinsho byori. The Japanese journal of clinical pathology

    2011  Volume 59, Issue 3, Page(s) 273–278

    MeSH term(s) Biomarkers/blood ; Cholesterol, LDL/blood ; Clinical Laboratory Techniques ; Humans ; Internal Medicine ; Pathology, Clinical/trends ; Social Medicine
    Chemical Substances Biomarkers ; Cholesterol, LDL
    Language Japanese
    Publishing date 2011-03
    Publishing country Japan
    Document type Journal Article ; Review
    ZDB-ID 604196-6
    ISSN 0047-1860 ; 0485-1404
    ISSN 0047-1860 ; 0485-1404
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 437: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Pitavastatin: clinical effects from the LIVES Study.

    Teramoto, Tamio

    Atherosclerosis. Supplements

    2011  Volume 12, Issue 3, Page(s) 285–288

    Abstract: Although clinical trials provide useful information on drug safety and efficacy, results do not always reflect those observed in the real world. The Japanese long-term prospective post-marketing surveillance LIVALO Effectiveness and Safety (LIVES) Study ... ...

    Abstract Although clinical trials provide useful information on drug safety and efficacy, results do not always reflect those observed in the real world. The Japanese long-term prospective post-marketing surveillance LIVALO Effectiveness and Safety (LIVES) Study was designed to assess the efficacy and safety of pitavastatin in clinical practice in ~20,000 patients. After 104 weeks, pitavastatin was associated with significant reductions in low-density lipoprotein-cholesterol (LDL-C) (29.1%) that largely occurred within 4 weeks of treatment initiation. In patients with abnormal triglyceride (TG) and high-density lipoprotein-cholesterol (HDL-C) levels at baseline, pitavastatin reduced TG and increased HDL-C by 22.7% and 19.9%, respectively. Overall, 88.2% of the primary prevention low-risk patients attained their Japan Atherosclerosis Society LDL-C target, compared with 82.7% of intermediate-risk patients, 66.5% of high-risk patients and 50.3% of secondary prevention patients. Only 10.4% of pitavastatin-treated patients experienced adverse events (AEs), of which approximately 84% were mild and around 1% was severe. Increases in blood creatine phosphokinase (2.7%), alanine aminotransferase (1.8%), myalgia (1.1%), aspartate aminotransferase (1.5%) and gamma-glutamyltransferase (1.0%) were the most common AEs and only 7.4% of patients discontinued pitavastatin due to AEs. Regression analysis demonstrated that age was not a significant factor for the incidence of any AE or myopathy-associated events. A subanalysis of initial LIVES data focussing on the effects of pitavastatin on HDL-C levels showed that HDL-C was elevated by 5.9% in all patients and by 24.6% in those with low (<l mmol/L; 40 mg/dL) HDL-C levels at baseline (P < 0.0001). A time-course analysis showed that the elevation in HDL-C in the low-HDL-C group was enhanced by 14.0% and 24.9% at 12 weeks and 104 weeks, respectively. In contrast, previous studies have shown that other statins have inconsistent effects on HDL-C levels, with elevations ranging from 0% to 12%. According to a LIVES subanalysis, pitavastatin produced a significant increase in HDL-C levels in patients switching from other statins, suggesting that patients with an unacceptably low level of HDL-C might benefit from switching to pitavastatin. Further analyses showed an improvement in HbA1c in patients with type 2 diabetes after long-term pitavastatin treatment and a significant increase in eGRF in patients with chronic kidney disease. Results from the 5-year LIVES extension study (N = 6,582) showed that long-term treatment with pitavastatin was well tolerated and that the reduction in LDL-C achieved after 104 weeks was maintained for the duration of treatment, whereas levels of HDL-C continued to rise. Importantly, multivariate analysis of the 5-year data showed that, in addition to advanced age (≥ 65 years), male gender, hypertension, diabetes, and a history of ischemic heart disease, on-treatment levels of HDL-C and LDL-C were significant predictors for cardiovascular (CV) and cerebrovascular risk. In this study, the greatest reduction in CV and cerebrovascular risk was achieved by patients achieving both their LDL-C and HDL-C targets. Overall, results from the LIVES study show that pitavastatin is well tolerated and effectively modifies atherogenic lipid profiles, thereby reducing CV and cerebrovascular risk in Japanese patients with hypercholesterolemia. Pitavastatin's ability to significantly and continually increase HDL-C levels over time suggests a particular benefit for patients with low baseline levels of HDL-C and/or those that fail to increase their HDL-C levels using alternative statins.<br />
    MeSH term(s) Atorvastatin Calcium ; Biomarkers ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/prevention & control ; Cerebrovascular Disorders/epidemiology ; Cerebrovascular Disorders/prevention & control ; Cholesterol, HDL/blood ; Cholesterol, LDL/blood ; Clinical Trials, Phase IV as Topic/methods ; Clinical Trials, Phase IV as Topic/statistics & numerical data ; Comorbidity ; Diabetes Mellitus, Type 2/blood ; Dyslipidemias/blood ; Dyslipidemias/drug therapy ; Glomerular Filtration Rate/drug effects ; Glycated Hemoglobin A/analysis ; Heptanoic Acids/therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Japan/epidemiology ; Kidney Diseases/blood ; Multicenter Studies as Topic/methods ; Multicenter Studies as Topic/statistics & numerical data ; Muscular Diseases/chemically induced ; Prospective Studies ; Pyrroles/therapeutic use ; Quinolines/adverse effects ; Quinolines/pharmacology ; Quinolines/therapeutic use ; Risk ; Simvastatin/therapeutic use ; Treatment Outcome ; Triglycerides/blood
    Chemical Substances Biomarkers ; Cholesterol, HDL ; Cholesterol, LDL ; Glycated Hemoglobin A ; Heptanoic Acids ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Pyrroles ; Quinolines ; Triglycerides ; Atorvastatin Calcium (48A5M73Z4Q) ; Simvastatin (AGG2FN16EV) ; pitavastatin (M5681Q5F9P)
    Language English
    Publishing date 2011-11
    Publishing country Netherlands
    Document type Journal Article ; Review
    ISSN 1878-5050
    ISSN (online) 1878-5050
    DOI 10.1016/S1567-5688(11)70888-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Book: Shishitsu ijōshō

    Teramoto, Tamio

    mansei shikkan yakubutsu ryōhō no tsubo

    2009  

    Abstract: It is necessary to try to obtain accurate informed consent from the patient in dyslipidemia treatment. On top of that, it is essential to treat it correctly depending on the state of the patient and to prevent arteriosclerosis. This book covers the basic ...

    Title variant Dyslipidemia
    Author's details henshū Teramoto Tamio
    Abstract It is necessary to try to obtain accurate informed consent from the patient in dyslipidemia treatment. On top of that, it is essential to treat it correctly depending on the state of the patient and to prevent arteriosclerosis. This book covers the basic information and the information needed in practical medical care.
    MeSH term(s) Dyslipidemias ; Dyslipidemias/drug therapy ; Chronic Disease/drug therapy
    Language Japanese
    Size 219 p. :, ill.
    Edition Dai 2-han.
    Publisher Nihon Iji Shinpōsha
    Publishing place Tōkyō
    Document type Book
    Note Rev. ed of: Kōshiketsushō : mansei shikkan yakubutsu ryōhō no tsubo. 2003.
    ISBN 9784784953844 ; 4784953841
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article: [Japan Atherosclerosis Society guidelines for prevention of atherosclerotic diseases in Japanese].

    Teramoto, Tamio

    Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics

    2009  Volume 45, Issue 6, Page(s) 597–600

    MeSH term(s) Aged ; Arteriosclerosis/prevention & control ; Female ; Guidelines as Topic ; Humans ; Japan ; Societies, Medical
    Language Japanese
    Publishing date 2009-01-05
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 604107-3
    ISSN 0300-9173
    ISSN 0300-9173
    DOI 10.3143/geriatrics.45.597
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1039: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Fragility Fracture Network-Japan: The challenge of establishment of a national hip fracture database and successful achievement of nationwide health system change for hip fracture care in Japan.

    Yamamoto, Noriaki / Sawaguchi, Takeshi / Matsushita, Takashi / Katoh, Narutaka / Arai, Hidenori / Shirahama, Masahiro / Endo, Naoto / Hagino, Hiroshi / Mori, Satoshi / Teramoto, Tamio / Ookuro, Masashi / Hiraoka, Mineko / Takahashi, Hideaki E

    Injury

    2024  , Page(s) 111452

    Abstract: Background: In April 2022, a new reimbursement scheme for hip fracture was implemented by the Japanese health ministry. Japan is one of the world's most aged societies, facing a significant, rapidly growing burden of osteoporosis and fragility fractures. ...

    Abstract Background: In April 2022, a new reimbursement scheme for hip fracture was implemented by the Japanese health ministry. Japan is one of the world's most aged societies, facing a significant, rapidly growing burden of osteoporosis and fragility fractures. The incidence of hip fractures is projected to increase from 240,000 in 2020 to 320,000 by 2040. In 2015, Fragility Fracture Network-Japan (FFN-Japan) was formally established as a nonprofit organization in order to create the optimal fragility fracture care system in Japan.
    Methods: FFN-Japan launched the Japan National Hip Fracture Database (JNHFD) in 2017, initially with only eight participating hospitals across Japan. The number of patients enrolled from May 2017 to the end of 2020 in the JNHFD from the 16 hospitals registered the patients during this period with amounting to 4271 patients in total. FFN-Japan invited officials from the Ministry of Health, Labor and Welfare (MHLW) to participate in round table meetings to discuss the data collected in the JNHFD and to consider opportunities for nationwide improvement in hip fracture care.
    Results: The proportion of patients who underwent surgery within 36 h of arrival at hospital was 48.1% in 2018, 58.6% in 2019, and 44.9% in 2020 indicating the delay of surgery. Regarding secondary fracture prevention, initiation of osteoporosis treatment during the in-patients was 60.2% in 2018, 54.0% in 2019, and 64.5% in 2020 indicating the inadequate post fracture care. In April 2022, the Central Social Insurance Medical Council of the Japanese MHLW announced a new reimbursement scheme for hip fracture care including two key components: Early surgery (within 48 h from injury) and Secondary fracture prevention immediately after fracture.
    Discussion: The new reimbursement scheme of hip fracture care in Japan will catalyze and underpin major improvements on acute multidisciplinary care and post-fracture care with secondary fracture prevention. FFN-Japan played a key role on these policy changes to the health system by means the close collaboration and ongoing communication with the government.
    Conclusion: Within five years of establishment of the JNHFD, FFN-Japan in collaboration with visionary leaders from the Japanese government have successfully achieved a major reform of the Japanese health system's reimbursement of hip fracture care. This reform has laid the foundation for transformation of management of this debilitating and life-threatening injury that currently afflicts almost a quarter of a million older Japanese citizens each year.
    Language English
    Publishing date 2024-03-02
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 218778-4
    ISSN 1879-0267 ; 0020-1383
    ISSN (online) 1879-0267
    ISSN 0020-1383
    DOI 10.1016/j.injury.2024.111452
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 778: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 10: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top